Cargando…
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study
OBJECTIVE: There is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among patients with ischaemic stroke on aspirin at...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256539/ https://www.ncbi.nlm.nih.gov/pubmed/25468508 http://dx.doi.org/10.1136/bmjopen-2014-006672 |
_version_ | 1782347598958428160 |
---|---|
author | Lee, Meng Wu, Yi-Ling Saver, Jeffrey L Lee, Hsuei-Chen Lee, Jiann-Der Chang, Ku-Chou Wu, Chih-Ying Lee, Tsong-Hai Wang, Hui-Hsuan Rao, Neal M Ovbiagele, Bruce |
author_facet | Lee, Meng Wu, Yi-Ling Saver, Jeffrey L Lee, Hsuei-Chen Lee, Jiann-Der Chang, Ku-Chou Wu, Chih-Ying Lee, Tsong-Hai Wang, Hui-Hsuan Rao, Neal M Ovbiagele, Bruce |
author_sort | Lee, Meng |
collection | PubMed |
description | OBJECTIVE: There is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among patients with ischaemic stroke on aspirin at the time of their index stroke. DESIGN: Retrospective. SETTING: We conducted a nationwide cohort study by retrieving all hospitalised patients (≥18 years) with a primary diagnosis of ischaemic stroke between 2003 and 2009 from Taiwan National Health Insurance Research Database. PARTICIPANTS: Among 3862 patients receiving aspirin before the index ischaemic stroke and receiving either aspirin or clopidogrel after index stroke during follow-up period, 1623 were excluded due to a medication possession ratio <80%. Also, 355 were excluded due to history of atrial fibrillation, valvular heart disease or coagulopathy. Therefore, 1884 patients were included in our final analysis. INTERVENTIONS: Patients were categorised into two groups based on whether clopidogrel or aspirin was prescribed during the follow-up period. Follow-up was from time of the index stroke to admission for recurrent stroke or myocardial infarction, death or the end of 2010. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary end point was hospitalisation due to a new-onset major adverse cardiovascular event (MACE: composite of any stroke or myocardial infarction). The leading secondary end point was any recurrent stroke. RESULTS: Compared to aspirin, clopidogrel was associated with a lower occurrence of future MACE (HR=0.54, 95% CI 0.43 to 0.68, p<0.001, number needed to treat: 8) and recurrent stroke (HR=0.54, 95% CI 0.42 to 0.69, p<0.001, number needed to treat: 9) after adjustment of relevant covariates. CONCLUSIONS: Among patients with an ischaemic stroke while taking aspirin, clopidogrel initiation was associated with fewer recurrent vascular events than aspirin reinitiation. |
format | Online Article Text |
id | pubmed-4256539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42565392014-12-09 Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study Lee, Meng Wu, Yi-Ling Saver, Jeffrey L Lee, Hsuei-Chen Lee, Jiann-Der Chang, Ku-Chou Wu, Chih-Ying Lee, Tsong-Hai Wang, Hui-Hsuan Rao, Neal M Ovbiagele, Bruce BMJ Open Cardiovascular Medicine OBJECTIVE: There is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among patients with ischaemic stroke on aspirin at the time of their index stroke. DESIGN: Retrospective. SETTING: We conducted a nationwide cohort study by retrieving all hospitalised patients (≥18 years) with a primary diagnosis of ischaemic stroke between 2003 and 2009 from Taiwan National Health Insurance Research Database. PARTICIPANTS: Among 3862 patients receiving aspirin before the index ischaemic stroke and receiving either aspirin or clopidogrel after index stroke during follow-up period, 1623 were excluded due to a medication possession ratio <80%. Also, 355 were excluded due to history of atrial fibrillation, valvular heart disease or coagulopathy. Therefore, 1884 patients were included in our final analysis. INTERVENTIONS: Patients were categorised into two groups based on whether clopidogrel or aspirin was prescribed during the follow-up period. Follow-up was from time of the index stroke to admission for recurrent stroke or myocardial infarction, death or the end of 2010. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary end point was hospitalisation due to a new-onset major adverse cardiovascular event (MACE: composite of any stroke or myocardial infarction). The leading secondary end point was any recurrent stroke. RESULTS: Compared to aspirin, clopidogrel was associated with a lower occurrence of future MACE (HR=0.54, 95% CI 0.43 to 0.68, p<0.001, number needed to treat: 8) and recurrent stroke (HR=0.54, 95% CI 0.42 to 0.69, p<0.001, number needed to treat: 9) after adjustment of relevant covariates. CONCLUSIONS: Among patients with an ischaemic stroke while taking aspirin, clopidogrel initiation was associated with fewer recurrent vascular events than aspirin reinitiation. BMJ Publishing Group 2014-12-02 /pmc/articles/PMC4256539/ /pubmed/25468508 http://dx.doi.org/10.1136/bmjopen-2014-006672 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Cardiovascular Medicine Lee, Meng Wu, Yi-Ling Saver, Jeffrey L Lee, Hsuei-Chen Lee, Jiann-Der Chang, Ku-Chou Wu, Chih-Ying Lee, Tsong-Hai Wang, Hui-Hsuan Rao, Neal M Ovbiagele, Bruce Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title | Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title_full | Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title_fullStr | Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title_full_unstemmed | Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title_short | Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study |
title_sort | is clopidogrel better than aspirin following breakthrough strokes while on aspirin? a retrospective cohort study |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256539/ https://www.ncbi.nlm.nih.gov/pubmed/25468508 http://dx.doi.org/10.1136/bmjopen-2014-006672 |
work_keys_str_mv | AT leemeng isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT wuyiling isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT saverjeffreyl isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT leehsueichen isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT leejiannder isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT changkuchou isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT wuchihying isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT leetsonghai isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT wanghuihsuan isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT raonealm isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy AT ovbiagelebruce isclopidogrelbetterthanaspirinfollowingbreakthroughstrokeswhileonaspirinaretrospectivecohortstudy |